In a recent review published in the Open Forum Infectious Diseases journal, researchers reported on the evolution of multidrug-resistant tuberculosis (MDR-TB) therapy. Study: At long last: short, ...

Please provide your email address to receive an email when new articles are posted on . Findings from a recent study support substituting bedaquiline for second-line injectables in treatment for ...

Please provide your email address to receive an email when new articles are posted on . Tuberculosis killed 1.6 million people in 2017 — more than 4,000 each day. Among its deadly attributes, TB is ...

resistance Punakha regimen not locked contentless cheese phase treatment locked contentregimen technology not four locked contentphase Tshechu treatment adults locked contentnot Bhutanese four to ...

Tuberculosis (TB) is the world's biggest infectious disease killer with multidrug-resistant TB (MDR-TB) posing a particular threat to global health. A study shows that resistance to the new MDR-TB ...

Shorter, six month and alloral treatment regimens for multidrugresistant and rifampicinresistant tuberculosis (MDR/RRTB) are ...

Tuberculosis (TB) disproportionately affects vulnerable populations including those with limited economic resources, HIV patients, those whose diet is deficient in nutrients and others. Resistant TB ...

There were an estimated 490,000 new cases of drug-resistant TB in 2016. Tuberculosis, a lung disease most often transmitted by breathing infected particles in the air, is the ninth leading cause of ...